Inpharma Weekly

, Volume 1015, Issue 1, pp 9–10 | Cite as

New antifungal agents needed for immunocompromised patients

  • Helen Mellsop
Newsletter Article


Several pharmaceutical companies worldwide have joined in a race to develop new antifungal agents for patients with compromised immune systems. Prominent at the 35th International Conference on Antimicrobial Agents and Chemotherapy [ San Francisco, US; September 1995 ] were presentations from Pfizer and Schering-Plough on their new azole derivatives UK-109496 and SCH-56592, which are at phase II and preclinical stages of development, respectively.


Fluconazole Itraconazole Candidiasis Azole Aspergillosis 

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Helen Mellsop

There are no affiliations available

Personalised recommendations